Stefan Kaufmann
Directeur/Membre du Conseil chez Bio Ventures for Global Health
Profil
Stefan Kaufmann is currently the Director at Bio Ventures for Global Health.
He is also a Member-Supervisory Board at Vakzine Projekt Management GmbH since 2012.
Previously, he worked at PricewaterhouseCoopers LLP.
Dr. Kaufmann was a Professor at Universität Ulm from 1987 to 1998.
He holds a doctorate degree from The Johannes Gutenberg University of Mainz and an undergraduate degree from Max-Planck-Institute for Molecular Genetics.
Postes actifs de Stefan Kaufmann
| Sociétés | Poste | Début |
|---|---|---|
Vakzine Projekt Management GmbH
 Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Corporate Officer/Principal | - |
| Bio Ventures for Global Health | Directeur/Membre du Conseil | - |
Anciens postes connus de Stefan Kaufmann
| Sociétés | Poste | Fin |
|---|---|---|
| Universität Ulm | Corporate Officer/Principal | 01/01/1998 |
Formation de Stefan Kaufmann
| Max-Planck-Institute for Molecular Genetics | Undergraduate Degree |
| The Johannes Gutenberg University of Mainz | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Health Technology |
| Bio Ventures for Global Health |